There is a lot of competition in specialty pharmacy right now, said Aimee Tharaldson, PharmD, a senior clinical consultant in Emerging Therapeutics for Express Scripts.
There is a lot of competition in specialty pharmacy right now, said Aimee Tharaldson, PharmD, a senior clinical consultant in Emerging Therapeutics for Express Scripts.
Transcript
What are some current key market trends in specialty pharmacy?
The FDA is definitely approving a lot of specialty drugs. In 2017, they approved 36 new specialty medications, and that’s just the trend that we’ve been seeing. When you look at drug spend under the pharmacy benefit, specialty drugs right now account for about 41% of spend. But, by 2019, we’re expecting about half of spend is going to be on specialty medications. Even though less than 2% of people take specialty drugs, they cost, on average, $3000 per month; so, they’re very expensive. So, that’s definitely where the market is focused.
We’re seeing a lot of competition in the specialty space now, so that’s even affecting orphan conditions, several cancer conditions, as well as more common specialty therapy classes. So, that potentially will lead to more cost-saving opportunity over time. We have specialty drugs going generic, too, which could have an impact. We recently had Copaxone go generic with the 40 mg strength. Zytiga, Gilenya, are some near-term ones that are going to be facing generic competition in the near future. So, that helps with competition.
We also have the biosimilars. So far, the FDA has approved 9 biosimilar medications. Unfortunately, only 3 have been launched. But, in the near future we are going to have more. We could have biosimilars to Epogen, Procrit this year, additional filgrastim biosimilars, Neulasta biosimilars. That could all occur this year. Even a Rituxan, which could happen sometime this year or next. Eventually, we’re going to have several biosimilars to Humira, so that’s really going to increase the competition and bring down the costs in the market.
So, competition is the main one I think.
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More